HLA Typing for Transplant Market 2018: Exploration on Eminent Players | Abbott Laboratories, Bio-Rad Laboratories, Bio-Reference Laboratories, CareDx, Inc., F. Hoffmann-La Roche Ltd., GenDx, Illumina Inc., Immucor Inc, Inno-train Diagnostik GmbH, Luminex

HLA Typing for Transplant Market size was valued over USD 330 million in 2016, with growth forecast over 10% CAGR from 2017 to 2024.

Amidst the currently expansive healthcare space, encompassing numerous verticals, HLA typing for transplant market has profoundly inked a rather progressive growth path, subject to the escalating requirement of organ transplantation which includes both cellular and humoral immune responses. As per clinical research, at least 6 HLA (Human Leukocyte Antigens) of the donor need to be matched with the organ receiver, since the success of stem cell transplantation is mainly dependent on the accuracy level of HLA matching among donors and receivers – higher the accuracy, lesser the complication risk. Having identified this potential factor and considered the benefits of human leukocyte antigens typing for transplants, many of the research institutes and diagnostics centers have been deploying this technique on large scale, thereby providing a positive impetus to HLA typing for transplant industry. It is prudent to state that the increasing use of advanced technologies across various healthcare facilities will help to identify and correlate the best possible transplant outcomes, further spurring HLA typing for transplant industry trends. Indeed, the growing acceptance of next-generation sequencing for organ transplantation will be one of the pivotal driving forces of HLA typing for transplant market size in the ensuing years.

Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/1653

At present, HLA typing for transplant industry is characterized by many research organizations and technology companies developing countable numbers of transplantation techniques and medicinal kits. In 2017 for instance, the Australian molecular diagnostic company, TBG Biotechnology, received the approval for its HLA genotyping kits for HCT (hematopoietic cell transplantation) from the China Food and Drug Administration (CFDA). After the approval, TBG apparently even collaborated with hematopoietic cell transplantation service providers and laboratory distributors, expanding the scope of HLA typing for transplant market. As per estimates, China is one of the largest consumers of allogeneic HCT market, therefore, increasing the rate of approval for HLA typing laboratories from CFDA is undeniably bound to stimulate China HLA typing transplant industry outlook.

In order to augment the revenue graph of HLA typing in transplant industry, renowned players have been focusing on technology development, discovery, and commercialization of high-value diagnostic methodologies for organ transplantation, on the grounds of which, companies are adopting advanced software-based technologies. For instance, last year, CareDx, Inc. acquired Assign™ SBT analysis software and Conexio SBT Resolver™ from Illumina, Inc. for improving high-resolution HLA typing. This technology apparently, has set a new benchmark ahead of several other biggies in HLA typing for transplant market with product innovation and high-quality HLA (Human Leukocyte Antigens) typing. This acquisition also helped CareDx to build its transplant business through the launch of new products and the commercialization of its existing portfolio. With firms such as CareDx and Illumina signing deals related to transplantation technology, next-generation sequencing system based HLA typing has gained remarkable momentum in recent years. In fact, after evaluating HLA typing results associated with next-generation sequencing based, one of the leading giants in NGS HLA typing transplantation and sequencing-based typing, based in Netherlands, GenDx signed an agreement with one of the well-known behemoths in HLA typing for transplant market, Thermo Fisher Scientific, to provide Ion PGM and NGSengine software to customers. The aforementioned detail validates that heavy investments in R&D activities to enhance existing technology will indeed fuel HLA typing for transplant industry share.

Make Inquiry about this report @ https://www.gminsights.com/inquiry-before-buying/1653

Organ transplant methods have indeed aided millions of patients, however, in order to increase the availability of organs, most giants in HLA typing for transplant market have been making heavy investments to research on more accurate and precise methodologies that would further promote the acceptance of transplantation technique across the globe. In consequence, this would have a profound impact on the revenue graph of HLA typing for transplant industry, slated to register a CAGR of 10% over 2017-2024.

Application of HLA typing in research is slated to increase at a lucrative pace owing to the spur in research and development activities being carried out to develop methods which are more advanced and accurate as compared to existing ones.

Hospital end user segment will grow at a rapid pace owing to the increasing number of organ transplant procedures being performed in these settings. Growing number of hospitals in several countries because of the healthcare infrastructure expansion plans will further augment segment growth.

Mexico HLA typing for transplant market is poised to grow at a lucrative rate over the forecast years owing to the increasing number of organ donations. Growing public awareness regarding importance of organ donation will further fuel growth. Campaigns such as ‘Héroes por la Vida’ (Heroes for Life) are being organized of sensitizing the masses and urging them to opt for organ donation.

India HLA typing for transplant market will grow at a robust rate owing to increasing awareness pertaining to diseases such as leukemia and thalassemia which require bone marrow transplants. Not for profit organizations such as MOHAN foundation are promoting organ donation through awareness campaigns, newsletters, patient support groups and network for organ sharing.

Prominent industry players include CareDx, Pacific Biosciences of California, Illumina, Thermo Fischer Scientific, GenDx and Immucor. The industry players employ various strategies such as distributor agreements, product portfolio expansion, acquisitions, collaborations and partnerships for increasing their industry shareholding. For instance, in July 2017, Thermo Fischer Scientific acquired Linkage Biosciences. Linkage Biosciences is now a part of Thermo Fischer’s transplant diagnostics business along with One Lambda. The acquisition has broadened the company’s product portfolio in turn strengthening its presence in the HLA typing for transplant industry.

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com

This release was published on openPR.